PRAKASH MASAND to Depressive Disorder, Major
This is a "connection" page, showing publications PRAKASH MASAND has written about Depressive Disorder, Major.
Connection Strength
1.575
-
Beyond serotonin: newer antidepressants in the future. Expert Rev Neurother. 2017 08; 17(8):777-790.
Score: 0.399
-
Quetiapine augmentation for depression: dosing pattern in routine practice. Int Clin Psychopharmacol. 2015 Jan; 30(1):54-8.
Score: 0.336
-
Aripiprazole augmentation for major depressive disorder: dosing patterns in a naturalistic treatment setting. Int Clin Psychopharmacol. 2014 Mar; 29(2):116-9.
Score: 0.317
-
Transdermal selegiline: the new generation of monoamine oxidase inhibitors. CNS Spectr. 2006 May; 11(5):363-75.
Score: 0.184
-
The effect of intravenous, intranasal, and oral ketamine in mood disorders: A meta-analysis. J Affect Disord. 2020 11 01; 276:576-584.
Score: 0.124
-
Adjunctive Brexpiprazole as a Novel Effective Strategy for Treating Major Depressive Disorder: A Systematic Review and Meta-Analysis. J Clin Psychopharmacol. 2017 Feb; 37(1):46-53.
Score: 0.097
-
A 6 week randomized double-blind placebo-controlled trial of ziprasidone for the acute depressive mixed state. PLoS One. 2012; 7(4):e34757.
Score: 0.070
-
A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression. J Clin Psychopharmacol. 2006 Dec; 26(6):653-6.
Score: 0.048